Type 2 Diabetes

Through clinical trials, investigators find that SGLT2 inhibitors are not only safe, but have several cardiovascular benefits.

The scope and scale of kidney disease is on the rise—much like its most commonly associated conditions.

FDA announced the approval of the glucagon (Gvoke) injection for the treatment of severe hypoglycemic events in diabetic patients ages 2 and up on September 10.

By allocating 1% of their day to exercise, patients can turn an unhealthy lifestyle into a healthy lifestyle.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

New findings from the THEMIS trial show patients with stable coronary artery disease and type 2 diabetes mellitus face major bleeding risks from the combination regimen.

Results of the DAPA-HF study — presented at the ESC Congress 2019, reveal use of dapagliflozin reduce hospitalizations from heart failure and deaths from cardiovascular causes in patients with heart failure with reduced ejection fraction.

The European Society of Cardiology and European Association for the Study of Diabetes released new diabetes and cardiovascular guidelines during ESC Congress 2019.

A recent review of adverse event reports from the FDA found that tramadol use was associated with a tenfold greater risk of developing hypoglycemia than most other opioids.

The SGLT-2 inhibitor is seeking an additional indication for primary renal outcome prevention in patients with or without type 2 diabetes.

New data suggests that type 2 diabetes linked to PTSD are less likely to occur among patients with clinically meaningful PTSD symptom reduction through treatment or spontaneous improvement.

The OneDraw A1C Test System was granted marketing clearance based on the strength of clinical findings reported at ADA 2019.

World Health Organization review finds that consumption of fish oil supplements have little to no impact on development or diagnosis of diabetes.

A recent analysis of the Asian Sudden Cardiac Death in Heart Failure registry found that type 2 diabetes mellitus was associated with structural changes of the heart and poorer quality of life.

Metformin as monotherapy is the preferred treatment for children and teens with type 2 diabetes, but a new study published in the Aug. 15 issue of the New England Journal of Medicine suggests that adding liraglutide to the treatment can more effectively control glycemic levels.

A single course of treatment with teplizumab significantly slowed the progression of type 1 diabetes in high-risk individuals who had not yet deveoped the condition, according to a study in the New England Journal of Medicine.

Children and adolescents have considerably fewer control therapy options for T2D. The GLP-1 agonist could be the first of its class for pediatric indication.

The committee meeting, tentatively scheduled for November 14, will have to precede the sNDA PDUFA action date set to review the drug's potential indication for reducing residual cardiovascular risks in patients with elevated triglycerides.

A recent study examining the effectiveness of an offline, automated smartphone-based AI system could be giving physicians a glimpse into the future of eye screening.

Steven Edelman, MD, clinical professor of medicine at UC San Diego, discusses glucose control among pediatric patients after a trial into the efficacy of inhaled insulin opened enrollment earlier this week.

A recent study published in the journal of the European Journal of Endocrinology found significant benefits of vitamin D supplementation on the development and progression of diabetes.

A systematic review and meta-analysis of observational studies assessing the association between plant-based dietary patterns and the risk of type 2 diabetes among adults, provides the strongest evidence to date that eating a plant-based diet does indeed lower the risk of type 2 diabetes.

Several new generics available to treat neuropathic pain linked to diabetic peripheral neuropathy, fibromyalgia partial onset seizures, and other conditions.

A recent study of more than 12 million people from 10 countries found that the risk of heart failure associated with diabetes was greater in women than in men. 



George Bakris, MD, outlines the difficulties clinicians face when treating diabetic kidney disease in an aging population.